Brainstorm Cell Therapeutics | BCLI - Operating Profit


Brainstorm Cell Therapeutics reported $-2.05M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Biogen USD 419.5M 663.3M Sep/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Cipla INR 10.43B 1.55B Sep/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -167.09M 12.08M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Mesoblast USD -20M 10.96M Jun/2026